Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

SF3B1 Mutations Promote Pervasive Metabolic Reprogramming and Enhanced Sensitivity to Glycolysis Inhibition

Matthew McLoughlin, Laura Bond, Guinevere Grice, Kenny Sham, Joshua Lee, Justyna Rak, Jake Tobin, Giampiero Valenzano, Ilias Moutsopoulos, Dimitris Lagos, James Nathan, Joanna Baxter, Irina Mohorianu, George S Vassiliou

Blood (2024) 144 (Supplement 1): 5726.

https://doi.org/10.1182/blood-2024-207364

Published: 2024

Journal Articles

Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2 V617F and Development of Myeloproliferative Neoplasms

Jyoti Nangalia, Jing Guo, Klaudia Walter, Pedro Quiros, Muxin Gu, E Joanna Baxter, John Danesh, Emanuele Di Angelantonio, David Roberts, Paola Guglielmelli, Claire N Harrison, Anna L Godfrey, Anthony R Green, George Vassiliou, Dragana Vuckovic, Nicole Soranzo

Blood (2023) 142 (Supplement 1): 863.

https://doi.org/10.1182/blood-2023-189551

Published: 2023

Journal Articles

Single-Cell Mutation Profiling and Alternative Splicing Analysis Reveals Distinct Aberrant Splicing of U2AF1 S34 and U2AF1 Q157 in Myeloid Malignancies

Sean Wen, Jennifer O Sullivan, Joanna Baxter, Nikolaos Sousos, Adam J Mead, Alba Rodriguez-Meira

Blood (2023) 142 (Supplement 1): 4133.

https://doi.org/10.1182/blood-2023-185999

Published: 2023

Journal Articles

Iron homeostasis governs erythroid phenotype in polycythemia vera

Blood (2023) 141 (26): 3199–3214.

https://doi.org/10.1182/blood.2022016779

Published: 2023

Includes: Supplemental data

Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-134764

Published: 2020

Journal Articles

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Blood (2018) 132 (Supplement 1): 98.

https://doi.org/10.1182/blood-2018-99-113495

Published: 2018

Journal Articles

Personalized Prognostic Predictions for Patients with Myeloproliferative Neoplasms through Integration of Comprehensive Genomic and Clinical Information

Blood (2017) 130 (Supplement 1): 491.

https://doi.org/10.1182/blood.V130.Suppl_1.491.491

Published: 2017

Journal Articles

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

Blood (2016) 128 (1): e1–e9.

https://doi.org/10.1182/blood-2015-11-683334

Published: 2016

Includes: Supplemental data

Journal Articles

Integration of innate into adaptive immune responses in ZAP-70–positive chronic lymphocytic leukemia

Michaela Wagner, Madlen Oelsner, Andrew Moore, Frederik Götte, Peer-Hendrik Kuhn, Torsten Haferlach, Michael Fiegl, Christian Bogner, E. Joanna Baxter, Christian Peschel, George A. Follows, Ingo Ringshausen

Blood (2016) 127 (4): 436–448.

https://doi.org/10.1182/blood-2015-05-646935

Published: 2016

Includes: Supplemental data

Journal Articles

R.I.S.C.L: A Holistic Molecular Diagnostic Tool for Myeloid Malignancies

Thomas D McKerrell, MD, Ignacio Varela, PhD, Nicolo Bolli, MD PhD, Postingl Hannes, PhD, Zemin Ning, PhD, German Tischler, PhD, Anthony Bench, PhD, Bridget Manasse, PhD, Joanna Baxter, PhD, Jorge Sierra, MD PhD, Dora Foukaneli, MD PhD, Allan Warren, MD PhD, Vincenza Colona, PhD, Chris Tyler-Smith, PhD, Brian Huntly, MD PhD, Josep F. Nomdedeu, MD, Mike Scott, PhD, George Vassiliou, MD PhD

Blood (2014) 124 (21): 2342.

https://doi.org/10.1182/blood.V124.21.2342.2342

Published: 2014

Journal Articles

Nongenetic stochastic expansion of JAK2V617F -homozygous subclones in polycythemia vera?

Anna L. Godfrey, Jyoti Nangalia, E. Joanna Baxter, Charles E. Massie, David G. Kent, Elli Papaemmanuil, Peter J. Campbell, Anthony R. Green

Blood (2014) 124 (22): 3332–3334.

https://doi.org/10.1182/blood-2014-09-603043

Published: 2014

Includes: Supplemental data

Journal Articles

Order Matters: Sequence Of Mutation Acquisition In Myeloproliferative Neoplasms Impacts Disease Pathogenesis and Stem Cell Potency

David G. Kent, PhD, Christina Ortmann, MD, Yvonne Silber, Joanna Baxter, PhD, Beatriz Bellosillo, Konstanze Doehner, MD, Peter J. Campbell, PhD, Anthony R Green

Blood (2013) 122 (21): 2888.

https://doi.org/10.1182/blood.V122.21.2888.2888

Published: 2013

Journal Articles

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Jyoti Nangalia, MBBChir FRCPath, Charles Massie, PhD, E Joanna Baxter, PhD, Francesca L Nice, MRes, Gunes Gundem, PhD, David Wedge, PhD, Edward Avezov, PhD, Juan Li, PhD, Karoline Kollmann, PhD, David G. Kent, PhD, Athar Aziz, PhD, Anna L Godfrey, BMBCh FRCPath, Jonathan Hinton, MSc, Inigo Martincorena, PhD, Peter Van Loo, PhD, Amy V Jones, PhD, Paola Guglielmelli, PhD MD, Patrick Tarpey, PhD, Heather P Harding, PhD, John D Fitzpatrick, BA, Calum T Goudie, BA, Christina A Ortmann, MD, Stephen J Loughran, PhD, Keiran Raine, MSc, David Jones, MSc, Adam Butler, MSc, Jon W Teague, MSc, Sarah O'Meara, Stuart McLaren, Michele Bianchi, Yvonne Silber, MSc, Danai Dimitropolou, BSc, David Bloxham, MSc FRCPath, Laura J Mudie, BSc, Mark Maddison, BSc, Ben Robinson, BSc, Clodagh Keohane, MD, Cathy MacLean, MSc, Kate Hill, BM BS, Kim H. Orchard, MBBS, PhD, FRCP, FRCPath, Sudhir Tauro, PhD, Ming-Qing Du, MB, PhD, Mel Greaves, PhD, FRS, David Bowen, MD, PhD, Brian Huntly, MBChB FRCPath PhD, Claire N Harrison, DM, FRCP, FRCPath, Nicholas C.P. Cross, PhD, FRCPath, David Ron, MD, Alessandro M Vannucchi, MD, Elli Papaemmanuil, PhD, Peter J. Campbell, PhD, Anthony R Green, FRCPath FMedSci

Blood (2013) 122 (21): LBA-2.

https://doi.org/10.1182/blood.V122.21.LBA-2.LBA-2

Published: 2013

Journal Articles

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

Peter J. Campbell, E. Joanna Baxter, Philip A. Beer, Linda M. Scott, Anthony J. Bench, Brian J. P. Huntly, Wendy N. Erber, Rajko Kusec, Thomas Stauffer Larsen, Stéphane Giraudier, Marie-Caroline Le Bousse-Kerdilès, Martin Griesshammer, John T. Reilly, Betty Y. Cheung, Claire N. Harrison, Anthony R. Green

Blood (2006) 108 (10): 3548–3555.

https://doi.org/10.1182/blood-2005-12-013748

Published: 2006

Journal Articles

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

Linda M. Scott, Peter J. Campbell, E. Joanna Baxter, Tony Todd, Philip Stephens, Sarah Edkins, Richard Wooster, Michael R. Stratton, P. Andrew Futreal, Anthony R. Green

Blood (2005) 106 (8): 2920–2921.

https://doi.org/10.1182/blood-2005-05-2087

Published: 2005

Journal Articles

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

Animesh Pardanani, Terra Reeder, Luis F. Porrata, Chin-Yang Li, Henry D. Tazelaar, E. Joanna Baxter, Thomas E. Witzig, Nicholas C. P. Cross, Ayalew Tefferi

Blood (2003) 101 (9): 3391–3397.

https://doi.org/10.1182/blood-2002-10-3103

Published: 2003

NARROW

SF3B1 Mutations Promote Pervasive Metabolic Reprogramming and Enhanced Sensitivity to Glycolysis Inhibition

Polygenic Germline Risk of Common Haematological Traits Drives Clonal Selection on JAK2 V617F and Development of Myeloproliferative Neoplasms

Single-Cell Mutation Profiling and Alternative Splicing Analysis Reveals Distinct Aberrant Splicing of U2AF1 S34 and U2AF1 Q157 in Myeloid Malignancies

Iron homeostasis governs erythroid phenotype in polycythemia vera

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Personalized Prognostic Predictions for Patients with Myeloproliferative Neoplasms through Integration of Comprehensive Genomic and Clinical Information

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

Integration of innate into adaptive immune responses in ZAP-70–positive chronic lymphocytic leukemia

R.I.S.C.L: A Holistic Molecular Diagnostic Tool for Myeloid Malignancies

Nongenetic stochastic expansion of JAK2V617F -homozygous subclones in polycythemia vera?

Order Matters: Sequence Of Mutation Acquisition In Myeloproliferative Neoplasms Impacts Disease Pathogenesis and Stem Cell Potency

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only